- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05184088
Efficacy of [18F]Florbetaben PET for Diagnosis of Cardiac AL Amyloidosis (CArdiag)
An Open-label, Multi-center, Non-randomized Pivotal Phase 3 Study to Evaluate the Efficacy and Safety of [18F]Florbetaben Positron Emission Tomography (PET) Imaging to Diagnose Cardiac AL Amyloidosis
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is an open-label, multi-center pivotal Phase 3 study to visually and quantitatively assess PET images obtained after single application of 300 MBq [18F]florbetaben and PET scanning of patients with suspected cardiac amyloidosis or with a putative diagnosis of cardiac amyloidosis but with remaining diagnostic uncertainty (e.g., unclear etiology or cardiac manifestation) or patients with diagnosis of amyloidosis but unclear cardiac involvement.
The diagnostic efficacy of the visual and quantitative assessments of [18F]florbetaben PET images for diagnosis of cardiac AL Amyloidosis will be determined by comparison to the standard of truth (SoT) obtained through standard of care clinical diagnosis.
Study Type
Enrollment (Estimated)
Phase
- Phase 3
Contacts and Locations
Study Contact
- Name: Aleksandar Jovalekic, PhD
- Phone Number: +49 (0)30 461 1246 03
- Email: clinicaltrials@life-mi.com
Study Contact Backup
- Name: Iris Hardewig, PhD
- Phone Number: +49 (0)30 461 1246 03
- Email: clinicaltrials@life-mi.com
Study Locations
-
-
-
Augsburg, Germany, 86156
- Recruiting
- University of Augsburg
-
Berlin, Germany, 13353
- Recruiting
- Charite Berlin
-
Essen, Germany, 45147
- Recruiting
- University of Essen
-
Hamburg, Germany, 22767
- Recruiting
- HOPA Hamburg
-
Heidelberg, Germany, 69120
- Recruiting
- University of Heidelberg
-
Würzburg, Germany, 97080
- Recruiting
- University of Würzburg
-
-
-
-
-
Barcelona, Spain, 08907
- Recruiting
- Hospital University Bellvitge
-
Madrid, Spain, 28222
- Recruiting
- Hospital University Puerta de Hierro
-
Pamplona, Spain, 31008
- Recruiting
- Clinica Universidad de Navarra
-
Salamanca, Spain, 37007
- Recruiting
- University of Salamanca
-
-
-
-
-
London, United Kingdom, NW3 2PF
- Recruiting
- Royal Free Hospital
-
-
-
-
Kansas
-
Kansas City, Kansas, United States, 64111
- Recruiting
- St Luke's Hospital
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- Recruiting
- University of Pennsylvania
-
Pittsburgh, Pennsylvania, United States, 15213
- Not yet recruiting
- University of Pittsburgh
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Males and females age ≥18 years
- Able to understand, sign and date written informed consent
- Written informed consent must be obtained before any assessment is performed
- Subjects being considered for a possible diagnosis of cardiac amyloidosis by
1. One of the following conditions:
- Established systemic amyloidosis without proven cardiac involvement,
- Known plasma cell dyscrasia (MGUS, multiple myeloma),
- Pathological free light chain levels in urine or serum,
- Presence of heart failure with preserved ejection fraction
2. AND one of the following parameters, indicative of cardiac manifestation:
- Mean (left ventricular (LV) wall + septum) thickness >12mm as measured by echocardiography in absence of other known cause of left ventricular hypertrophy (LVH),
- NT-proBNP >335 ng/L
- Planned diagnostic procedure to establish diagnosis and cardiac involvement (e.g., endomyocardial biopsy or extracardiac biopsy in conjunction with cardiac magnetic resonance imaging/echocardiography or bone scintigraphy)
- Female subjects must be documented by medical records or physician's note to be either surgically sterile (by means of hysterectomy, bilateral salpingectomy, or bilateral oophorectomy) or post-menopausal for at least 1 year (no menses for 12 months without an alternative medical cause). If they are of child-bearing potential, they must commit to use of a highly effective contraceptive measure for at least one week following the PET scan
- Male subjects and their partners of childbearing potential must commit to the use of a highly effective method of contraception for a minimum of 90 days following the PET scan
- Male subjects must commit to not donate sperm for a minimum of 90 days after the PET scan
Exclusion Criteria:
- Any known allergic reactions or hypersensitivity towards any compound of the study drug
- Severe hepatic impairment (AST/ALT >5 x ULN; bilirubin >3 x ULN)
- Inability to lay flat for up to 60 min
- Pregnant, lactating or breastfeeding
- Unwilling and/or unable to cooperate with study procedures
- Having been administered a radiopharmaceutical within 10 radioactive half-lives prior to study drug administration in this study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Patients with suspected cardiac amyloidosis
After enrolment, patients will be subjected to diagnostic procedures according to standard of care to resolve diagnostic uncertainties and to clarify possible cardiac involvement.
The results of the clinical work-up will be used a standard of truth, i.e. patients with initially suspected cardiac amyloidosis that where subsequently clinically diagnosed with cardiac AL Amyloidosis, cardiac ATTR Amyloidosis, other cardiac Amyloidosis or non cardiac amyloidosis.
|
All enrolled patients will undergo [18F]florbetaben PET imaging.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Sensitivity and specificity of the visual assessment of [18F]florbetaben PET images for the diagnosis of cardiac AL amyloidosis.
Time Frame: Up to 12 weeks
|
The results from the visual assessment of [18F]florbetaben PET images are compared to the clinical diagnosis established through histological verification of the presence or absence of AL amyloidosis with cardiac involvement determined either through endomyocardial biopsy or through extracardiac biopsy in conjunction with typical CMR or echocardiography imaging features as the standard of truth.
|
Up to 12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Sensitivity and specificity of [18F]florbetaben PET for the diagnosis of cardiac AL amyloidosis using quantification.
Time Frame: Up to 12 weeks
|
The sensitivity and specificity of [18F]florbetaben PET for the diagnosis of cardiac AL amyloidosis will be determined by using quantitative image analysis.
|
Up to 12 weeks
|
Correlation of quantitative [18F]florbetaben PET results with left ventricular ejection fraction (LV EF) and left ventricular mass (LV mass).
Time Frame: Up to 12 weeks
|
Correlation of quantitative [18F]florbetaben PET results with left ventricular ejection fraction (LV EF) and left ventricular mass (LV mass).
|
Up to 12 weeks
|
Correlation of quantitative [18F]florbetaben PET results with AL CA stage I - IV based on FLC-diff, cTnT and NT-proBNP levels.
Time Frame: Up to 12 weeks
|
Correlation of quantitative [18F]florbetaben PET results with AL CA stage I - IV based on FLC-diff, cTnT and NT-proBNP levels.
|
Up to 12 weeks
|
Impact of PET imaging (AL-CA/non AL-CA) on diagnostic thinking and patient management will be assessed with physician's questionnaires before and after the diagnostic work-up, and after receipt of the PET results.
Time Frame: Up to 14 weeks
|
The impact of PET imaging (AL-CA/non AL-CA) on diagnostic thinking and patient management will be assessed with physician's questionnaires before and after the diagnostic work-up, and after receipt of the PET results.
|
Up to 14 weeks
|
Number of adverse events
Time Frame: Up to 17 days after imaging visit
|
Safety will be evaluated by collection of Adverse Events.
|
Up to 17 days after imaging visit
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Sensitivity and specificity of [18F]florbetaben PET images for a differential diagnosis between AL CA, ATTR CA and non CA will be assessed.
Time Frame: Up to 12 weeks
|
In this exploratory endpoint the sensitivity and specificity of [18F]florbetaben PET images for a differential diagnosis between AL CA, ATTR CA and non CA will be assessed.
|
Up to 12 weeks
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Director: Andrew Stephens, MD, PhD, Life Molecular Imaging
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- FBB-02-01-21
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on AL Amyloidosis
-
Nexcella Inc.Not yet recruitingLight Chain (AL) AmyloidosisUnited States
-
Peking Union Medical College HospitalRecruitingLight Chain (AL) Amyloidosis | Venetoclax | CCND1 TranslocationChina
-
Sorrento Therapeutics, Inc.WithdrawnLight Chain (AL) Amyloidosis
-
Boston Medical CenterMillennium Pharmaceuticals, Inc.Completed
-
European Myeloma NetworkJanssen PharmaceuticaActive, not recruitingLight Chain (AL) Amyloidosis, Stage 3BNetherlands, Greece, France, Italy
-
Tufts Medical CenterSanofiWithdrawnAmyloidosis | Light Chain (AL) Amyloidosis
-
Sorrento Therapeutics, Inc.RecruitingLight Chain (AL) AmyloidosisUnited States
-
Weill Medical College of Cornell UniversityJanssen Scientific Affairs, LLCRecruitingAL Amyloidosis | Amyloid | Refractory AL AmyloidosisUnited States
-
IRCCS Policlinico S. MatteoTerminatedCardiac AL AmyloidosisSpain, France, Italy, Germany, Canada, Greece, Turkey, United Kingdom
-
Nanjing University School of MedicineRecruiting
Clinical Trials on [18F]florbetaben
-
Adam BrickmanNational Institute on Aging (NIA)Completed
-
Columbia UniversityNational Institute on Aging (NIA)RecruitingAlzheimer DiseaseUnited States
-
IRCCS Policlinico S. MatteoRecruiting
-
National Institute on Alcohol Abuse and Alcoholism...CompletedNormal PhysiologyUnited States
-
Sinotau Pharmaceutical GroupCompletedMental Disorders | Brain Diseases | Central Nervous System Diseases | Nervous System Diseases | Neurocognitive Disorders | Neurodegenerative Diseases | Dementia | Alzheimer Disease | TauopathiesChina
-
James M Noble, MD, MS, CPH, FAANNational Institute on Aging (NIA)RecruitingAlzheimer DiseaseUnited States
-
Central Hospital, Nancy, FranceCompleted
-
Ulsan University HospitalCompletedMultiple MyelomaKorea, Republic of
-
Fundacion Clinic per a la Recerca BiomédicaUnknownSubjective Cognitive Decline
-
Molecular NeuroImagingLife Molecular Imaging SACompletedAlzheimer's Disease (AD) | Progressive Supranuclear Palsy (PSP) | Frontal Temporal Dementia (FTD) | Cortical Basal Syndrome (CBS)United States